Engineers have developed a lipid nanoparticle (LNP) that delivers mRNA therapeutic to the placenta to treat pre-eclampsia in mice with human trials on the horizon. Penn Engineers have made a ...

Lipid nanoparticles (LNPs) are primed to revolutionize the development of nucleic acid therapies. The trusted lipid experts at Cayman Chemical provide industry-leading solutions for every stage of LNP ...

Lipid nanoparticle (LNP) technology is increasingly enabling the clinical potential of genetic drugs. By packaging the nucleic acid polymer in well-defined nanoparticles, LNPs protect the nucleic acid ...

Malignant tumors remain a serious threat to human health and life and are a major public health problem globally. Herein, we ...

Lipid nanoparticles (LNPs) transport small molecules into the body. The most well-known LNP cargo is mRNA, the key constituent of some of the early vaccines against COVID-19. But that is just one ...

Middlemen get a bad rap for adding cost and complications to an operation. So, eliminating the go-betweens can reduce expense ...

What is Nanoparticle Tracking Analysis? Nanoparticle Tracking Analysis (NTA) is a powerful technique for characterizing nanoparticles in solution. It combines laser light scattering microscopy with a ...

Lipid nanoparticles have been studied since the 1960s, but widespread use and optimization of delivery for mRNA therapeutics, including vaccines, really came to the forefront during COVID-19.

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought ...

In previous research, Swingle conducted a successful proof-of-concept study that examined a library of lipid nanoparticles (LNPs), the delivery molecules that helped get the mRNA of the COVID ...

In previous research, Swingle conducted a successful proof-of-concept study that examined a library of lipid nanoparticles (LNPs), the delivery molecules that helped get the mRNA of the COVID ...